Safety of the oxaliplatin readministration by the desensitization for metastatic colorectal cancer patients having oxaliplatin allergy

Safety of the oxaliplatin readministration by the desensitization for metastatic colorectal cancer patients having oxaliplatin allergy - Safety of the oxaliplatin readministration by the desensitization for metastatic colorectal cancer patients having oxaliplatin allergy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010128

Enrollment

Registered

2013-02-28

Start date

2013-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal carcinoma

Interventions

desensitization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histopathologically confirmed colorectal adenocarcinoma (2) Unresectable or recurrent colorectal cancer (3) Prior chemotherapy history for metastatic colorectal cancer (4) History of Grade2-3 oxaliplatin allergy,and reappearance Grade2-3 oxaliplatin allergy in spite of premedication with corticosteroids and antagonists of histamine receptors (5) Treated with oxaliplatin-based chemotherapy (6) What type of regimen (7) Life expectancy estimated more than 2 months (8) Aged over 20 years at the time of registration (9) Performance status(ECOG) 0-2 (10) With or without measurable region (11) Adequate organ function (12) Grade1 toxicity for chemotherapy, radiotherapy or surgery (13) Written informed consent

Exclusion criteria

Exclusion criteria: 1 History of desensitization for oxaliplatin 2 history of oxaliplatin hypersensitivity Grade4 3 Uncontrollable diabetes mellitus 4 Regularly using steroid 5 Uncontrollable heart disease 6 Other severe complications such as renal failure liver failure and intestinal pneumonitis 7 Symptomatic CNS metastasis 8 Active bacterial or fungous infection 9 Massive pleural effusion or massive ascites 10 Active bleeding 11 Active double cancer 12 Patient evaluated to be inadequate by a attending doctor 13 Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
the rate of oxaliplatin readministration without allergy	—

Countries

Japan

Contacts

Public ContactYukiya Narita

Aichi Cancer Center Hospital Department of Clinical Oncology

052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026